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Abstract
The development of molecular signatures for the prediction of time-to-event outcomes is
a methodologically challenging task in bioinformatics and biostatistics. Although there are
numerous approaches for the derivation of marker combinations and their evaluation, the
underlying methodology often suffers from the problem that different optimization criteria
are mixed during the feature selection, estimation and evaluation steps. This might result
in marker combinations that are suboptimal regarding the evaluation criterion of interest.
To address this issue, we propose a unified framework to derive and evaluate biomarker
combinations. Our approach is based on the concordance index for time-to-event data,
which is a non-parametric measure to quantify the discriminatory power of a prediction
rule. Specifically, we propose a gradient boosting algorithm that results in linear biomarker
combinations that are optimal with respect to a smoothed version of the concordance index.
We investigate the performance of our algorithm in a large-scale simulation study and in two
molecular data sets for the prediction of survival in breast cancer patients. Our numerical
results show that the new approach is not only methodologically sound but can also lead to a
higher discriminatory power than traditional approaches for the derivation of gene signatures.
Introduction
Recent technological developments in the fields of genomics and biomedical research have led to
the discovery of large numbers of gene signatures for the prediction of clinical survival outcomes.
In cancer research, for example, gene expression signatures are nowadays used to predict the
time to occurrence of metastases [1, 2] as well as the time to progression [3] and overall patient
survival [4, 5]. While the importance of molecular data in clinical and epidemiological research
is expected to grow considerably in the next years [6, 7, 8], the detection of clinically useful gene
signatures remains a challenging problem for bioinformaticians and biostatisticians, especially
when the outcome is a survival time.
After normalization and data pre-processing, the development of a new gene signature usually
comprises three methodological tasks:
Task 1: Select a subset of genes that is associated with the clinical outcome.
∗ This is a preliminary version of an article submitted to PLOS ONE. If citing, please refer to the original
article.
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Task 2: Derive a marker signature by finding the “optimal” combination of the selected
genes.
Task 3: Evaluate the prediction accuracy of the optimal combination using future or
external data.
Task 1, the selection of a clinically relevant subset of genes, is often addressed by calculating
scores to rank the univariate association between the survival outcome and each of the genes
[9, 8]. In a subsequent step, the genes with the strongest associations are selected to be included
in the gene signature.
Task 2, the derivation of an optimal combination of the selected genes, is usually fulfilled by
forming linear combinations of gene expression levels based on Cox regression. Due to multi-
collinearity problems and the high dimensionality of molecular data, a direct optimization of
the Cox partial likelihood is often unfeasible [8]. Consequently, marker combinations are of-
ten derived by combining coefficients of univariate Cox regression models [10], or by applying
regularized Cox regression techniques (such as the Lasso [11, 12] or ridge-penalized regression
[13, 14]).
Task 3, the evaluation of prediction accuracy, is considered to be a challenging problem in
survival analysis. This is because traditional performance measures for continuous outcomes
(such as the mean squared error) are no longer applicable in the presence of censoring. In the
literature, several approaches to address this problem exist (see, e.g., [15] for an overview). In
this article, we focus on the concordance index for time-to-event data (C-index [16, 17, 18]),
which has become a widely used measure of the performance of biomarkers in survival studies
[19, 20, 21, 22]. Briefly spoken, the C-index can be interpreted as the probability that a patient
with a small survival time is associated with a high value of a biomarker combination (and
vice versa). Consequently, it measures the concordance between the rankings of the survival
times and the biomarker values and therefore the ability of a biomarker to discriminate between
patients with small survival times and patients with large survival times. This strategy is
especially helpful if the aim is to subdivide patients into groups with good or poor prognosis
(as applied in many articles in the medical literature, e.g., [10]). By definition, the C-index
has the same scale as the classical area under the curve (AUC) in binary classification: While
prediction rules based on random guessing yield C = 0.5, a perfectly discriminating biomarker
combination leads to C = 1.
Interestingly, the derivation of new gene signatures for survival outcomes via Tasks 1–3 is often
addressed by combining completely different methodological approaches and estimation tech-
niques. For example, the estimation of biomarker combinations is usually based on Cox re-
gression and is hence carried out via the optimization of a partial likelihood criterion. On the
other hand, the resulting combinations are often evaluated by using the C-index [21, 22] which
has its roots in the receiver operating characteristics (ROC) methodology. This methodological
inconsistency is also problematic from a practical point of view, as the marker combination
that optimizes the partial log likelihood criterion is not necessarily the one that optimizes the
C-index. In other words, if the C-index and therefore the discriminatory power is the evaluation
criterion of interest, it may be suboptimal to use a likelihood-based criterion to optimize the
marker combination. This issue is, of course, not only problematic in survival analysis but also
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in regression and classification. A theoretical discussion on the differences between performance
measures for binary classification can, e.g., be found in [23].
To overcome the aforementioned inconsistencies, we propose a unified framework for survival
analysis that is based on the same statistical methodology for gene selection (Task 1), derivation
of an optimal biomarker combination (Task 2) and the evaluation of a new gene signature (Task
3). As will be demonstrated, all three tasks can be addressed by using the concordance index
for time-to-event data as performance criterion. While the C-index has already been proposed
for gene selection (Task 1) and the evaluation of prediction accuracy (Task 3) [9, 15], the main
contribution of this article is a new estimation technique that addresses the development of
optimal combinations of genes (Task 2). To achieve this goal, we propose a method for finding
gene combinations that is based on the gradient boosting framework [24]. As will be shown, it is
possible to use boosting to derive prediction-optimized gene combinations via direct optimization
of the C-index. Because this new approach allows for using the C-index to address all three
tasks, the proposed method leads to a consistent framework for the derivation of gene signatures
in biomarker studies where the C-index is the main performance criterion.
Methods
Notation
We first introduce some basic notation that will be used throughout the article. Let T ∈ R+
be the survival time of interest and X = (x1, ..., xp) ∈ R
p a vector of predictor variables. In
addition to the gene expression levels, X may contain the measurements of some clinical predictor
variables. Denote the conditional survival function of T given X by S(t|x) = P(T > t|X = x).
The probability density and survival functions of T are denoted by f(t) and S(t), respectively.
Further let Tcens ∈ R
+ be a random censoring time and denote the observed survival time by
T˜ := min(T, Tcens). The random variable ∆ := I(T ≤ Tcens) indicates whether T˜ is right-censored
(∆ = 0) or not (∆ = 1).
A prediction rule for T will be formed as a linear combination
η := β0 +
p∑
l=1
βl · xl = X
⊤β , (1)
where β is an unknown vector of coefficients. We generally assume that the estimation of βˆ is
based on an i.i.d. learning sample {(T˜Li ,∆
L
i ,X
L
i ), i = 1, . . . , n}. In case of the Cox regression
model, for example, η is related to T by the equation
S(t|x) = exp
(
− Λ0(t) · exp
(
η
))
, (2)
where Λ0(t) is the cumulative baseline hazard function. Because there is a one-to-one relationship
between η and the expected survival time E(T |X), the linear combination η can be used as a
biomarker to predict the survival of individual patients.
3
Concordance index
Our proposed framework to derive and evaluate biomarker combinations is based on the con-
cordance index (“C-index”) which is a general discrimination measure for the evaluation of
prediction models [16, 17]. It can be applied to continuous, ordinal and dichotomous outcomes
[25]. For time-to-event outcomes, the C-index is defined as
C := P(ηj1 > ηj2 |Tj1 < Tj2) , (3)
where Tj1 , Tj2 and ηj1 , ηj2 are the event times and the predicted marker values, respectively, of
two observations in an i.i.d. test sample {(T˜j ,∆j,Xj), j = 1, . . . , N}. By definition, the C-index
for survival data measures whether large values of η are associated with short survival times T
and vice versa. Moreover, it can be shown that the C-index is equivalent to the area under the
time-dependent ROC curve, which is a measure of the discriminative ability of η at each time
point under consideration (see [26], p. 95 for a formal proof).
During the last decades, the C-index has gained enormous popularity in biomedical research; for
example, searching for the terms “concordance index” and “c-index” in PubMed [27] resulted in
1156 articles by the time of writing this article. Generally, a value of C close to 1 indicates that
the marker η is close to a perfect discriminatory power, while a marker that does not perform
better than chance results in a value of 0.5. For example, the famous Gail model [28] for the
prediction of breast cancer is estimated to yield a value of C = 0.67 [29].
Being a flexible discrimination measure, the C-index is especially useful for selecting and ranking
genes from a pre-processed set of high-dimensional gene expression data (Task 1 described in the
Introduction). In other words, Task 1 can be addressed by computing the C-index (and hence
the marginal discriminatory power) for each individual gene or biomarker, where only those
genes with the highest C-index are incorporated into the yet-to-derive optimal combination
(Task 2). Although there exist various other ways to rank genes and select the most influential
ones, the C-index has been demonstrated to be especially advantageous for this task [9].
An estimator of the C-index for survival data is given by
Ĉsurv :=
∑
j<k I
(
T˜j < T˜k
)
I (ηˆj > ηˆk)∆j + I
(
T˜k < T˜j
)
I (ηˆk > ηˆj)∆k∑
j<k I
(
T˜j < T˜k
)
∆j + I
(
T˜k < T˜j
)
∆k
(4)
with j, k ∈ {1, . . . , n} (“Harrell’s C for survival data”, [30]). Generally, Ĉsurv is a consistent
estimator of the C-index in situations where no censoring is present. However, because pairs
of observations where the smaller observed survival time is censored are ignored in formula (4),
Ĉsurv is known to show a notable upward bias in the presence of censoring. This bias tends to
be correlated with the censoring rate [30, 15].
To overcome the censoring bias of Ĉsurv, Uno et al. [18] proposed a modified version of Ĉsurv,
which is defined as
ĈUno :=
∑
j,k(Gˆ
L
n(T˜j))
−2 I
(
T˜j < T˜k
)
I (ηˆj > ηˆk)∆j∑
j,k(Gˆ
L
n(T˜j))
−2 I
(
T˜j < T˜k
)
∆j
, (5)
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where GˆLn(t) denotes the Kaplan-Meier estimator of the unconditional survival function of Tcens
(estimated from the learning data). In the following, we will assume that the censoring times
are independent of X. Under this assumption, ĈUno is a consistent and asymptotically normal
estimator of C (see [18], pp. 1113–1115). Consistency is ensured by applying inverse probability
weighting (using the weights ∆j/(Gˆ
L
n (T˜j)
2), which account for the inverse probability that an
observation in the test data is censored [31]). Numerical studies suggest that ĈUno is remarkably
robust against violations of the random censoring assumption [32].
Apart from the estimators Ĉsurv and ĈUno, there exist various other approaches to estimate
the probability in (3) (see, e.g., [15] for an overview). Most of these approaches are based on
the assumptions of a Cox proportional hazards model, so that they are not valid in case these
assumptions are violated. Because ĈUno is model-free and because the consistency of ĈUno is
guaranteed even in situations where censoring rates are high (in contrast to the estimator Ĉsurv),
we will base our boosting method on ĈUno.
Boosting the concordance index
The core of our proposed framework to address Tasks 1 – 3 is the derivation of a prediction-
optimized linear combination of genes that is optimal w.r.t. to the C-index for time-to-event
data. Our approach will be based on a component-wise gradient boosting algorithm [24] that
uses the C-index as optimization criterion.
Gradient boosting algorithms [33] are generally based on a loss function ρ(T, η) that is assumed
to be differentiable with respect to the predictor η ≡ η(X). The aim is then to estimate the
“optimal” prediction function
η∗ := argmin
η
ET,X [ρ(T, η(X))] (6)
by using gradient descent techniques. As the theoretical mean in (6) is usually unknown in
practice, gradient boosting algorithms minimize the empirical risk R :=
∑n
i=1 ρ(ti, η(xi)) over η
instead.
When considering the C-index for survival data, the aim is to determine the optimal predictor η∗
that maximizes the concordance measure C = P(η∗i > η
∗
k |Ti < Tk) – which is essentially the
solution to Task 2. Hence a natural choice for the empirical risk function R would be the
negative concordance index estimator
− ĈUno(T, η) = −
∑
i,k∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
)
I (ηi > ηk)∑
i,k∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
) . (7)
Setting R = −ĈUno(T, η), however, is unfeasible because ĈUno(T, η) is not differentiable with
respect to ηi and can therefore not be used in a gradient boosting algorithm. To solve this
problem, we follow the approach of Ma and Huang [34] and approximate the indicator function
in (7) by the sigmoid function K(u) = 1/(1 + exp(−u/σ)). Here, σ is a tuning parameter that
controls the smoothness of the approximation (details on the choice of σ will be given in the
Numerical Results section). Replacing the indicator function in (7) by its smoothed version
results in the smoothed empirical risk function
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− Ĉsmooth(T, η) = −
∑
i,k
wik ·
1
1 + exp
(
ηˆk−ηˆi
σ
) (8)
with weights
wik :=
∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
)
∑
i,k∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
) . (9)
By definition, the smoothed empirical risk −Ĉsmooth(T, η) is differentiable with respect to the
predictor ηi. Its derivative is given by
−
∂ Ĉsmooth(T, η)
∂ ηi
= −
∑
k
wik
− exp
(
ηˆk−ηˆi
σ
)
σ
(
1 + exp
(
ηˆk−ηˆi
σ
)) . (10)
In the next step of the gradient boosting algorithm, the derivative in (10) is iteratively fitted
to a set of base-learners. Typically, an individual base-learner (simple regression tool, e.g., a
tree or a simple linear model) is specified for each marker. To ensure that the estimate of the
optimal predictor η∗ is a linear combination of the components of X, we will apply simple linear
models as base-learners (cf. [35]). In other words, each base-learner is a simple linear model
with one component of X as input variable. Consequently, there are p base-learners, which will
be denoted by bl, l = 1, . . . , p. Each base-learner refers to one component of X and therefore to
one marker (or gene).
The component-wise gradient boosting algorithm for the optimization of the smoothed C-index
is then given as follows:
(1) Initialize the estimate of the marker combination ηˆ[0] with offset values. For example,
set ηˆ[0] = 0, leading to βˆ
[0]
l = 0 for all components l = 1, . . . , p. Choose a sufficiently large
maximum number of iterations mstop and set the iteration counter m to 1.
(2) Compute the negative gradient vector by using formula (10) and evaluate it at the marker
combination ηˆ[m−1] of the previous iteration:
U [m] =
(
U
[m]
i
)
i=1,...,n
:=
(
∂ Ĉsmooth(T, ηˆ
[m−1])
∂ ηi
)
i=1,...,n
.
(3) Fit the negative gradient vector U [m] separately to each of the components of X via the
base-learners bl(·):
U [m]
fitted by
−−−−−−→ bˆ
[m]
l (xl) for l = 1, ..., p.
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(4) Select the component l∗ that best fits the negative gradient vector according to the least
squares criterion, i.e., select the base-learner bl∗ defined by
l∗ = argmin
1≤l≤p
n∑
i=1
(
U
[m]
i − bˆ
[m]
l (xl)
)2
.
(5) Update the marker combination ηˆ for this component:
ηˆ[m] ← ηˆ[m−1] + sl · bˆ
[m]
l∗ (xl∗) ,
where sl is a small step length (0 < sl ≪ 1). For example, if sl = 0.1, only 10% of the
fit of the base-learner is added to the current marker. This procedure shrinks the effect
estimates towards zero, effectively increasing the numerical stability of the update step
[23, 25].
As only the base learner bˆl∗ was selected, only the effect of component l
∗ is updated
(βˆ
[m]
l∗ = βˆ
[m−1]
l∗ + sl · bˆ
[m]
l∗ (xl∗)) while all other effects stay constant (βˆ
[m]
l = βˆ
[m−1]
l for
l 6= l∗).
(6) Stop if m = mstop. Else increase m by one and go back to step (2).
By construction, the proposed boosting algorithm automatically estimates the optimal linear
biomarker combination that maximizes the smoothed C-index. The principle behind the pro-
posed algorithm is to minimize the empirical risk R = −Ĉsmooth(T, η) by using gradient descent
in function space, where the function space is spanned by the base-learners bl, l = 1, ..., p. In
other words, the algorithm iteratively descents the empirical risk by updating ηˆ[m] via the best
fitting base-learner. Because the base-learners are simple linear models (each containing only
one possible biomarker as predictor variable) and because the update in step (5) of the algorithm
is additive, the final solution ηˆ[mstop] effectively becomes a linear combination of these markers.
The two main tuning parameters of gradient boosting algorithms are the stopping iteration mstop
and the step length sl. In the literature it has been argued that the choice of the step length
is of minor importance for the performance of boosting algorithms [36]. Generally, a larger
step length leads to faster convergence of the algorithm. However, it also increases the risk of
overshooting near the minimum of R. In the following sections we will use a fixed step-length of
sl = 0.1, which is a common recommendation in the literature on gradient boosting [36, 37] (and
which is also the default value in the R package mboost [38]). The stopping iteration mstop is
considered to be the most important tuning parameter of boosting algorithms [37]. The optimal
value of mstop is usually determined by using cross-validation techniques [24]. Small values of
mstop reduce the complexity of the resulting linear combination ηˆ
[mstop] and avoid overfitting
via shrinking the effect estimates. In case of boosting the C-index, however, overfitting is less
problematic as the predictive performance of η is not related to the actual size of the coefficients
but to the concordance of the rankings between marker values and the observed survival times.
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As a result, the stopping iteration mstop in this specific case is less relevant and can be also
specified by a fixed large value (e.g., mstop = 50000).
Regarding the boosting algorithm for the smoothed C-index, an additional tuning parameter is
given by the smoothing parameter σ. While too large values of σ will lead to a poor approxi-
mation of the indicator functions in (7), too small values of σ might overfit the data (and might
therefore result in a decreased prediction accuracy). Details on how to best choose the value of
σ will be given in the Numerical Results section.
The boosting algorithm presented above is implemented in the add-on software package mboost
of the open source statistical programming environment R [39]. The specification of the new
Cindex() family and a short description of how to apply the algorithm in practice are given in
the Appendix.
Evaluation
After having applied the C-index to select the most influential genes (Task 1), and after having
used the proposed boosting algorithm to combine the selected genes (Task 2), a final challenge
is to evaluate the prediction accuracy of the resulting gene combination (Task 3). Since the
C-index was used for Tasks 1 and 2, it is also a natural criterion to evaluate the derived marker
combination in Task 3. As argued before, it is advantageous from both a methodological per-
spective as well as from a practical one to use the same criterion for estimation and evaluation
of a biomarker combination.
To avoid over-optimistic estimates of prediction accuracy, it is crucial to use different ob-
servations for the optimization and evaluation of the marker signature [25, 40]. This can
be achieved either by using two completely different data sets (external evaluation) or by
splitting one data-set into a learning sample {(T˜Li ,∆
L
i ,X
L
i ), i = 1, . . . , n} and a test sample
{(T˜j ,∆j,Xj), j = 1, . . . , N}. The learning sample is used to optimize the marker combination
while the “external” test sample serves only for evaluation purposes. A more elaborate strategy
is subsampling (such as five-fold or ten-fold cross-validation), which is based on multiple random
splits of the data. In our numerical analysis, we will use subsampling techniques in combination
with stratification to divide the underlying data sets into learning and test samples (for details,
see the next section).
When it comes to the C-index, two additional points have to be taken into consideration: First,
as the task is to obtain the most precise estimation for the discriminatory power, it is no longer
necessary to use the smoothed version Ĉsmooth (which was included for numerical reasons in the
boosting algorithm) for evaluation. Consequently, we propose to apply the original estimator
ĈUno for evaluating biomarker combinations in Task 3. Second, when applying the estimator
ĈUno to the observations in a test sample, a natural question is how to calculate the Kaplan-
Meier estimator GˆLn(t) of the unconditional survival function of Tcens. In principle, there are
three possibilities for the calculation of GˆLn(t): The Kaplan-Meier estimator can be computed
from either the test or from the training data, or, alternatively, from the combined data set
containing all observations in the learning and test samples. Following the principle that all
estimation steps should be carried out prior to Task 3, we will base computation of the Kaplan-
Meier estimator on the learning data.
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Numerical results
Simulation study
We first investigated the performance of our approach based on simulated data. The aim of our
simulation study was:
(i) To analyze if the proposed framework is able to select a small amount of informative
markers from a much larger set of candidate variables.
(ii) To check if gradient boosting is able to derive the optimal combination η of the selected
markers, and to compare its performance to competing Cox-based estimation schemes.
(iii) To investigate the effect of the smoothing parameter σ that controls the smoothness inside
the sigmoid function, as well as potential effects of the sample size and the censoring rate
on the performance of our approach.
The simulated survival times are generated via a log-logistic distribution for accelerated failure
time (AFT) models [41]. They are based on the model equation log(T ) = µ+φW , where T is the
survival time, µ and φ are location and scale parameters, and W is a noise variable, following a
standard logistic distribution. As a result, the density function for realizations ti can be written
as
fdens(ti|µi, φi) =
exp ((ti − µi)/φi)
φi (1 + exp ((ti − µi)/φi))
2 (11)
with E(T ) = µ and Var(T ) = pi
2
3φ2
. The p = 1000 possible markers X1, ....,X1000 were drawn
from a multivariate normal distribution with pairwise correlation (ρ = 0.5). The true underlying
combinations of the predictors were given by
µi = ηµ = 1.5 + 1.5x1 + x2 − x3 − 1.5x4 ,
log(φi) = ηφ = −1 + 2x1 − 2x2 + x3 − x4 .
Note that only four out of 1000 possible markers have an actual effect on the survival time.
Furthermore, those four markers do not only contribute to the location parameter µ but also
to the scale parameter φ (cf. [42]) – a setting where standard survival analysis clearly becomes
problematic. Additionally to the survival times T , we generated an independent sample of
censoring times Tcens and defined the observed survival time by T˜ := min(T, Tcens) leading to
independent censoring of 50% of the observations.
In order to answer the above questions, we investigated the performance of our framework in all
three tasks that are necessary to develop new gene signatures in practice (Tasks 1–3 described in
the Introduction). To avoid over-optimism and biased results, we simulated separate data sets
for the different tasks. In B = 100 simulation runs, we first simulated a data set {(T˜i,∆i,Xi), i =
1, . . . , 1000} with 1000 observations to pre-select the most influential predictors based on the
C-index (Task 1). The optimal combination η of those predictors was later estimated (Task
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Figure 1: Coefficient estimates for p∗ = 5 pre-selected markers obtained from 100 sim-
ulation runs. The marker combinations were optimized via gradient boosting based on training
samples of size n = 100 (left) and n = 500 (right). Boxplots represent the empirical distribution of
the resulting coefficients. Only markers X1 to X4 had an actual effect on the survival time.
2) by our boosting algorithm based on smaller training samples {(T˜Li ,∆
L
i ,X
L
i ), i = 1, . . . , n}
of size n. For the final external evaluation of the prediction accuracy (Task 3) we simulated a
separate test data set {(T˜j ,∆j ,Xj), j = 1, . . . , N} with N = 1000.
For Task 1, we first pre-selected a subset of p∗ predictors from the p = 1000 available markers.
We ranked the predictors based on their individual values of CˆUno and included only the p
∗ =
{5, 10, 30} best-performing markers in the boosting algorithm. The results suggest that the
C-index is clearly able to identify markers that are truly related to the outcome: Although all
predictors had a relatively high pairwise correlation (ρ = 0.5), the four informative markers had
a selection probability of 98.5% for p∗ = 5 (99% for p∗ = 10 and 99.5% for p∗ = 30).
To find the optimal combination η of the pre-selected markers (Task 2), we applied the proposed
boosting approach on training samples with size n = 100. The resulting coefficients for p∗ = 5
and smoothing parameter σ = 0.1 are presented in Figure 1. The boosting algorithm seems to
be able to derive the optimal combination of the pre-selected markers, as the structure displayed
by the coefficients is essentially the same as the one of the underlying true combination ηµ. The
discriminatory power of the resulting biomarker does not depend on the absolute size of the
coefficients: As the C-index is based solely on the concordance between biomarker and survival
time, what matters in practice is the relative size of the coefficients. As can be seen from
Figure 1, the estimated positive effect for x1 is larger than the one for x2. On the other hand,
the negative effect of x4 is correctly estimated to be more pronounced than the the one of x3.
The coefficient of the falsely selected marker is on average close to zero.
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setting method
n p∗ cens. C-index boosting Cox lasso Cox ridge true C-index
100 5 50% 0.764 (0.04) 0.731 (0.06) 0.739 (0.04) 0.779
100 10 50% 0.746 (0.06) 0.709 (0.08) 0.707 (0.06) 0.779
100 30 50% 0.689 (0.07) 0.673 (0.11) 0.637 (0.07) 0.779
100 5 30% 0.820 (0.02) 0.774 (0.04) 0.724 (0.04) 0.830
100 5 70% 0.668 (0.10) 0.628 (0.10) 0.593 (0.11) 0.690
50 5 50% 0.741 (0.07) 0.662 (0.18) 0.722 (0.09) 0.772
200 5 50% 0.774 (0.02) 0.748 (0.04) 0.752 (0.04) 0.782
500 5 50% 0.778 (0.03) 0.759 (0.03) 0.760 (0.02) 0.781
Table 1: Results of the simulation study. Comparison of the discriminatory power resulting
from boosting the C-index with competing approaches. Numbers refer to the median value and
interquartile range (in parentheses) of the final CˆUno on 100 simulation runs. The true C-index
refers to the discriminatory power resulting from the true combination of predictors with known
coefficients. The amount of pre-selected genes is denoted as p∗, n is the size of the training samples
and cens. refers to the censoring rate.
In a third step, we evaluated the performance of the resulting optimized marker combinations
(Task 3) on separate test samples. The resulting estimates CˆUno for different simulation settings
are presented in Table 1. The highest discriminatory power (median CˆUno = 0.763, range =
0.559–0.819) can be observed for p∗ = 5, which is closest to the true number of informative
markers. We compared the performance of our proposed algorithm to penalized Cox regression
approaches such as Cox-Lasso [11, 12] and Cox regression with ridge-penalization [13, 14] –
see Figure 2. The proposed boosting approach clearly outperforms the competing estimation
schemes, supporting our view that applying traditional Cox regression might be suboptimal if
the discriminatory power is the performance criterion of interest. We additionally computed the
optimal C-index resulting from the true marker combination ηµ with known coefficients. The
values of the true C-index on the test samples are on average only slightly better than the ones
of boosting the concordance index (median CˆUno = 0.778 – see Table 1).
To evaluate the possible effects of different sample sizes and censoring rates we modified the mean
censoring time leading to approximate censoring rates of 30% and 70% and generated training
samples of size n = {50, 200, 500}. Results are included in Table 1. As expected, the C-index
resulting from our framework increases as censoring rates become small (median CˆUno = 0.820,
range = 0.736–0.858) and decreases in settings with a large proportion of censored observations
(median CˆUno = 0.668, range = 0.421–0.776). However, the same effect can be observed for the
true C-index resulting from the true marker combination ηµ (30% censoring CˆUno = 0.830, 70%
censoring CˆUno = 0.690). For larger training samples, the variance of the coefficient estimates
decreases (see Figure 1). As a result, the discriminatory power resulting from our boosting
algorithm improves (for n = 500, median CˆUno = 0.778, range = 0.614–0.818) and gets nearly
as good as the true C-index (CˆUno = 0.781). This finding further confirms the ability of our
approach to find the most optimal marker combination possible – see Figure 2. Note that also
the true C-index differs slightly between the different sample sizes, as the training sample enters
in CˆUno via the Kaplan-Meier estimator Gˆ
L
n(t).
11
Figure 2: Simulation results for the discriminatory power obtained via the proposed
C-index boosting approach and competing Cox-based estimation schemes. The marker
combinations were optimized via the different approaches based on training samples of size n = 100
(left) and n = 500 (right). Boxplots represent the empirical distribution of the resulting CˆUno on
corresponding test samples. The dotted line corresponds to the discriminatory power resulting from
the true combination of predictors with known coefficients.
To investigate the effect of the smoothing parameter inside the sigmoid function, we additionally
applied our boosting procedure for every simulation setting with different values of σ. The
resulting estimates CˆUno are presented in Table 2. Compared to the effects of the sample size or
the number of pre-selected markers p∗, the smoothing parameter σ only seems to have a minor
effect on the performance of our algorithm. In light of these empirical results, we recommend to
apply a fixed small value (e.g., σ = 0.1, which is also the default value in the Cindex() family
for the mboost package [38] – see the Appendix).
For both approaches to fit penalized Cox regression (Cox lasso, Cox ridge), we applied the
R add-on package penalized [43]. In order to evaluate CˆUno, we used the UnoC() function
implemented in the survAUC package [44].
Applications to predict the time to distant metastases
In the next step, we further analyzed the performance of our gradient boosting algorithm in two
applications to estimate and evaluate the optimal combination of pre-selected biomarkers. All
markers are used to predict the time to distant metastases in breast cancer patients. As in the
simulation study, we compared the results of our proposed algorithm to Cox regression with lasso
and ridge penalization. Additionally, we considered four competing boosting approaches for sur-
vival analysis, which do not directly optimize the C-index. The first is classical Cox regression,
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setting smoothing parameter
n p∗ cens. σ = 0.5 σ = 0.25 σ = 0.1 σ = 0.075 σ = 0.05
100 5 50% 0.738 (0.06) 0.757 (0.05) 0.764 (0.04) 0.763 (0.04) 0.762 (0.04)
100 10 50% 0.728 (0.06) 0.744 (0.06) 0.746 (0.06) 0.746 (0.06) 0.741 (0.05)
100 30 50% 0.700 (0.06) 0.702 (0.07) 0.689 (0.07) 0.683 (0.07) 0.666 (0.07)
100 5 30% 0.802 (0.03) 0.815 (0.02) 0.820 (0.02) 0.821 (0.02) 0.822 (0.02)
100 5 70% 0.665 (0.10) 0.667 (0.10) 0.668 (0.10) 0.665 (0.10) 0.661 (0.10)
50 5 50% 0.719 (0.07) 0.737 (0.07) 0.741 (0.07) 0.740 (0.06) 0.725 (0.06)
200 5 50% 0.743 (0.05) 0.768 (0.03) 0.774 (0.02) 0.775 (0.02) 0.778 (0.02)
500 5 50% 0.723 (0.05) 0.769 (0.02) 0.778 (0.03) 0.779 (0.03) 0.781 (0.03)
Table 2: Simulation results for different values of the smoothing parameter. Comparison
of the discriminatory power resulting from the gradient boosting approach when applying different
values of the smoothing parameter σ. Numbers refer to to the median value and interquartile range
(in parentheses) of the final CˆUno on 100 simulation runs. The amount of pre-selected genes is
denoted as p∗, n is the size of the training samples and cens. refers to the censoring rate. We
recommend to use the value σ = 0.1, which is also the default value of the new Cindex family for
the R add-on package mboost.
estimated via gradient boosting, while the other three are parametric accelerated failure-time
(AFT) models assuming a Weibull, log-normal or log-logistic distribution [45, 46]. For all boost-
ing approaches (Weibull AFT boosting, loglog-AFT boosting and Cox boosting) we used the
corresponding pre-implemented functions of the mboost package. To ensure comparability, we
used the same linear base-learners as described above for all boosting approaches.
To ensure that the combined predictor did not only work on the data it was derived from but
also on “external” validation data, we carried out a subsampling procedure for both data sets
to generate B = 100 different learning samples {(T˜Li ,∆
L
i ,X
L
i ), i = 1, . . . , n} and test samples
{(T˜j ,∆j,Xj), j = 1, . . . , N}, respectively. Consequently, we randomly split the corresponding
data sets to use 2/3 of the observations as learning sample in order to optimize the biomarker
combination ηˆ. To ensure an equal distribution of patients with and without an observed
development of distant metastases we applied stratified sampling. Correspondingly, the 1/3
of the observations not included in the learning sample were used to evaluate the resulting
predictions via the C-index. As a result, for every data set and every method we computed 100
different combinations η and 100 corresponding values of CˆUno.
Breast cancer data by Desmedt et al.
Desmedt et al. [1] collected a data set of 196 node-negative breast cancer patients to validate
a 76-gene expression signature developed by Wang et al. [10]. The signature, which is based
on Affymetrix microarrays, was developed separately for estrogen-receptor (ER) positive pa-
tients (60 genes) and ER-negative patients (16 genes). In addition to the expression levels of
the 76 genes, four clinical predictor variables were considered (tumor size, estrogen receptor
(ER) status, grade of the tumor and patient age). The data are publicly available on GEO
(http://www.ncbi.nlm.nih.gov/geo, accession number GSE 7390).
Similar to Wang et al. [10], we used the time from diagnosis to distant metastases as pri-
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mary outcome and considered the 76 genes together with the four clinical predictors. Observed
metastasis-free survival ranged from 125 days to 3652 days, with 79.08% of the survival times
being censored.
The main results of our analysis are presented in Figure 3. As expected, the unified framework
to estimate and evaluate the optimal marker signature based on the C-index is not only method-
ologically more consistent than the Cox and AFT approaches, but also leads to to marker signa-
tures that show a higher discriminatory power on external or future data (median CˆUno = 0.736,
range = 0.467–0.854). As discussed in the methodological section, it is crucial to evaluate the
discriminatory power on external data: the estimated C-index on the training sample was more
than 35% higher (median CˆUno = 0.986) and hence extremely over-optimistic [25, 40].
Considering the interpretation of the resulting coefficient estimates for the clinical predictors, it
is crucial to note that boosting methods for the C-index and the AFT models yield biomarker
combinations η∗ where larger values indicate longer predicted survival times. On the other
hand, classical Cox regression models rely on the hazard; higher values are hence associated
with smaller survival times. If this is taken into account, results from the different approaches
were in fact very similar. Both age of the patients and size of the tumor had a negative effect on
the time to recurrence for all seven approaches. The same holds true for the tumor grade poor
differentiation which resulted in a negative effect compared to good differentiation and inter-
mediate differentiation. A positive ER status, on the other hand, was associated with a larger
metastasis-free survival in all approaches. Regarding the coefficients of the 76 genes, results
from our approach to boost the C-index were highly correlated to the ones of the other four
boosting approaches (which rely on the same base-learners) – absolute correlation coefficients
computed from the 100 subsamples ranged from 0.77 to 0.99. Also coefficients resulting from the
popular ridge-penalized Cox regression were highly correlated with the ones from our approach
– absolute correlation coefficients ranged from 0.47 to 0.84.
Breast cancer data by van de Vijver et al.
The second data set consists of 144 lymph node positive breast cancer patients that was collected
by the Netherlands Cancer Institute [2]. The data set, which is publicly available as part of the
R add-on package penalized [43], was used by van de Vijver et al. [2] to validate a 70-gene
signature for metastasis-free survival after surgery developed by van’t Veer et al. [47]. In addition
to the expression levels of the 70 genes, the data set contains five clinical predictor variables
(tumor diameter, number of affected lymph nodes, ER status, grade of the tumor and patient
age). Observed metastasis-free survival times ranged from 0.055 months to 17.660 months, with
67% of the survival times being censored.
Resulting values of the C-index of the new approach and the six considered competitors are
presented in Figure 3. The improvement from applying the proposed unified framework com-
pared to boosting the Cox proportional hazard model or applying ridge-penalized Cox regression
was much less pronounced than in the previous data set. However, on average, boosting the
C-index still led to the best combination of markers regarding the discriminatory power (median
CˆUno = 0.662, range = 0.257–0.836). Interestingly, as in the previous data set, the lasso penal-
ized Cox regression was clearly outperformed by the ridge-penalized competitor (which has been
suggested for this specific data set by van Houwelingen et al. [48]). Furthermore, the ridge-
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Figure 3: Comparing the discriminatory power of biomarker combinations to predict
the time to distant metastases resulting from the proposed C-index boosting approach with
competing estimation schemes. The plot on the left refers to the Desmedt et al. data, whereas the
plot on the right presents results from the van de Vijver et al. data. All biomarker combinations
were optimized via the corresponding algorithms based on the same 100 learning samples. Boxplots
represent the empirical distribution of the resulting CˆUno on corresponding test samples. The dotted
line corresponds to the median C-index resulting from the new approach.
penalized approach performed at least as good as the considered boosting approaches (except the
new approach to boost the C-index). As in the previous data set, we again additionally evaluated
the C-index on the training sample in order to assess the resulting over-optimism. As expected,
the estimated C-index on the training sample was extremely biased (median CˆUno = 0.973).
The resulting coefficients for the clinical predictors were again comparable for the seven different
approaches. A positive ER status was associated with a larger metastasis-free survival for all
seven approaches, the same also holds true for the age of the patient. On the other hand, the
size of the tumor, the number of affected lymph nodes and a poor tumor grade resulted for all
approaches in a negative effect on the survival time. Regarding the coefficients of the 79 genes,
the highest correlation could again be observed for the boosting algorithms: Absolute correlation
coefficients obtained from the 100 subsamples ranged from 0.64 to 0.95. Correlation between
coefficients resulting from our approach to boost the C-index and the ones from ridge-penalized
Cox regression was slightly lower, it ranging from 0.30 to 0.82.
Discussion
In this article we have proposed a framework for the development of survival prediction rules that
is based on the concordance index for time-to-event data (C-index). As the C-index is an easy-to-
interpret measure of the accuracy of survival predictions (based on clinical or molecular data), it
has become an important tool in medical decision making. Generally, the focus of the C-index is
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on measuring the “discriminatory power” of a prediction rule: It quantifies how well the rankings
of the survival times and the values of a biomarker (or marker combinations) in a sample agree.
In particular, the C-index is methodologically different from measures that evaluate how well
a prediction rule is “calibrated” (i.e., from measures that quantify “how closely the predicted
probabilities agree numerically with the actual outcomes” [49]). Specifically, prediction rules
that are well calibrated do not necessarily have a high discriminatory power (and vice versa).
While several authors have proposed the use of the C-index for feature selection [9] and the
evaluation of molecular signatures [21, 22], the main contribution of this paper is a new approach
for the derivation of marker combinations that is based directly on the C-index. Consequently,
when using the proposed method, it is no longer necessary to rely on traditional methods such
as Cox regression – which focus on the derivation of well-calibrated prediction rules instead of
well-disciminating prediction rules and may therefore be suboptimal when the optimization of
the discriminatory power is of main interest.
Conceptually, our approach is in direct line with recent articles by Ma and Huang [34], Wang
and Chang [50] and Schmid et al. [51] who developed a set of algorithms for the optimization of
discrimination measures for binary outcomes (such as the area under the curve (AUC) and the
partial area under the curve and (PAUC)). Because the C-index is in fact a summary measure of
a correspondingly defined AUC measure for time-to-event data [26], our optimization technique
relies on similar methodological concepts, such as the application of boosting methods and the
use of smoothed indicator functions.
A possible future extension of our approach might be to include the task of selecting the most
influential genes in the proposed boosting algorithm. While our simulation study and the breast-
cancer examples were based on the pre-selection of genes, the proposed boosting method could
also be applied directly to high-dimensional molecular data, so that Tasks 1 and 2 are effectively
combined. This can be accomplished by optimizing the stopping iteration so that only a (low-
dimensional) subset of the candidate genes is incorporated in the resulting marker combination
(“early stopping”, cf. [37]). Further research is warranted on the issues of early stopping and
automated feature selection in the case of boosting the concordance index for survival data.
The results of our empirical analysis suggest that the new approach is competitive with state-of-
the-art methods for the derivation of marker combinations. As demonstrated in the Numerical
Results section, the resulting marker combinations are not only easy to compute and have a
meaningful interpretation but can also lead to a higher discriminatory power of the resulting
gene signatures.
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Appendix
Gradient boosting of the C-index
The concept of boosting was first introduced in the field of machine learning [52, 53]. The
basic idea is to boost the accuracy of a relatively weak performing classificator (termed “base-
learner”) to a more accurate prediction via iteratively applying the base-learner and aggregating
its solutions. Generally, the concept of boosting leads to a drastically improved prediction
accuracy compared to a single solution of the base-learner [54]. This basic concept was later
adapted to fit statistical regression models in a forward stagewise fashion [33, 35]. One of the
main advantages of this approach is the interpretability of the final solution, which is basically
the same as in any other statistical model [24]. This can not be achieved with competing machine
learning algorithms as Support Vector Machines [55] or Random Forests [56]. Specifically, the
boosting approach can be used to develop prediction rules for survival outcomes [45, 46, 57].
Although there exist also likelihood-based approaches for boosting [58], we will focus here on
gradient-based boosting [24] as it is the better fitting approach for boosting the distribution-free
C-index.
The most flexible implementation of gradient boosting is the mboost [38] add-on package for the
Open Source programming environment R [39]. The mboost package contains a large variety of
different pre-implemented base-learners and loss functions, that can be combined by the user
via different fitting functions. For a tutorial on the how to apply the package for practical data
analysis, see [59].
To apply gradient boosting to optimize linear biomarker combinations w.r.t. the C-index in the
version of Uno et al. [18], it is necessary to specify the newly developed Cindex() family inside
the glmboost() function.
The Cindex family object includes the sigmoid function K(u) = 1/(1 + exp(−u/σ)) as approxi-
mation of the indicator functions in the estimated C-index. The sigmoid function is evaluated
inside the R functions approxGrad() and approxLoss(), which are part of the Cindex object.
The weights
wik :=
∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
)
∑
i,k∆i (Gˆ
L
n(T˜i))
−2 I
(
T˜i < T˜k
) (12)
are computed via the internal function compute weights() for both the empirical risk
− Ĉsmooth(T, η) = −
∑
i,k
wik ·
1
1 + exp
(
ηˆk−ηˆi
σ
) (13)
(implemented in the risk() function) as well as for the negative gradient
−
∂ Ĉsmooth(T, η)
∂ ηi
= −
∑
k
wik
− exp
(
ηˆk−ηˆi
σ
)
σ
(
1 + exp
(
ηˆk−ηˆi
σ
)) (14)
(implemented in the ngradient() function).
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Those different functions that define the optimization problem are finally plugged into the
mboost specific Family() function to build a new boost family. Details on how to implement
user-specific families in mboost are presented in the Appendix of [59]. The complete Cindex
object is then given as follows:
Cindex <- function (sigma = 0.1) {
approxGrad <- function(x) { ## sigmoid function for gradient
exp(x/sigma) / (sigma * (1 + exp(x/sigma))^2)
}
approxLoss <- function(x) { ## sigmoid function for loss
1 / (1 + exp(x / sigma))
}
compute_weights <- function(y, w = 1){ ## compute weights
ipcw_wow <- IPCweights(y[w != 0,])
ipcw <- numeric(nrow(y))
ipcw[w!=0] <- ipcw_wow
survtime <- y[,1]
n <- nrow(y)
wweights <- matrix( (ipcw)^2, nrow = n, ncol = n)
weightsj <- matrix(survtime, nrow = n, ncol = n)
weightsk <- matrix(survtime, nrow = n, ncol = n, byrow = TRUE)
weightsI <- (weightsj < weightsk) + 0
wweights <- wweights * weightsI
Wmat <- w %o% w
wweights <- wweights * Wmat
wweights <- wweights / sum(wweights)
rm(weightsI); rm(weightsk); rm(weightsj)
return(wweights)
}
ngradient = function(y, f, w = 1) { ## negative gradient
if (!all(w %in% c(0,1)))
stop(sQuote("weights"), " must be either 0 or 1 for family ",
sQuote("UnoC"))
survtime <- y[,1]
event <- y[,2]
if (length(w) == 1) w <- rep(1, length(event))
if (length(f) == 1) {
f <- rep(f, length(survtime))
}
n <- length(survtime)
etaj <- matrix(f, nrow = n, ncol = n, byrow = TRUE)
etak <- matrix(f, nrow = n, ncol = n)
etaMat <- etak - etaj
rm(etaj); rm(etak);
weights_out <- compute_weights(y, w)
M1 <- approxGrad(etaMat) * weights_out
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ng <- colSums(M1) - rowSums(M1)
return(ng)
}
risk = function(y, f, w = 1) { ## empirical risk
survtime <- y[,1]
event <- y[,2]
if (length(f) == 1) {
f <- rep(f, length(y))
}
n <- length(survtime)
etaj <- matrix(f, nrow = n, ncol = n, byrow = TRUE)
etak <- matrix(f, nrow = n, ncol = n)
etaMat <- (etak - etaj)
rm(etaj); rm(etak);
weights_out <- compute_weights(y, w)
M1 <- approxLoss(etaMat) * weights_out
return(- sum(M1))
}
Family( ## build the family object
ngradient = ngradient,
risk = risk,
weights = "zeroone",
offset = function(y, w = 1) {0},
check_y = function(y) {
if (!inherits(y, "Surv"))
stop("response is not an object of class ", sQuote("Surv"),
" but ", sQuote("family = UnoC()"))
y},
rclass = function(f){},
name = paste("Concordance Probability by Uno")
)
}
Application
We will briefly demonstrate how to apply the Cindex family in practice to derive the optimal
combination of pre-selected biomarkers. We will use the van de Vijver et al. [2] data set of
144 lymph node positive breast cancer patients that was also considered in the main article.
The data set is publicly available as part of the R add-on package penalized [43]. The 70-gene
signature for metastasis-free survival after surgery was originally developed by van’t Veer et al.
[47].
We first split the data set in 100 training observations and 44 test observations. To ensure
better readability of the code we do not carry out stratified subsampling but just use the first
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100 patients as training sample. Model fitting is carried out by the glmboost() function of the
mboost package. As linear models are the default base-learners for glmboost(), no additional
base-learner has to be specified. As appropriate family object we specify the Cindex family
described above.
For evaluating the discriminatory power of the resulting prediction on test data, we use the
UnoC() function of the survAUC package [44]. It implements the unbiased estimator ĈUno, as
proposed by Uno et al. [18].
## load add-on packages
library(penalized) ## for the data set
library(mboost) ## for boosting
library(survAUC) ## for evaluation
data(nki70) ## loading the data
source("Cindex.R") ## loading the family defined above
## split the data set in training and test sample (simplified):
dtrain <- nki70[1:100,]
dtest <- nki70[101:144,]
## fit a model via the glmboost() function
## formula : defines the candidate model; the response is the survival
## object Surv(time, event); via ’~ ." all remaining variables
## in the data set serve as possible predictors
## family : defines the optimization problem (in this case the C-index)
## sigma is the smoothing parameter of the sigmoid function that
## approximates the indicator functions. The default value is 0.1.
## control : defines other boosting-specific tuning parameters like the
## stopping iteration mstop or the step-length nu; trace = TRUE is
## only for convenience (shows the trace of the empirical risk).
## data : defines the data set -> training sample
mod1 <- glmboost(Surv(time, event) ~ ., family = Cindex(sigma = 0.1),
control = boost_control(mstop = 500, trace = TRUE, nu = 0.1),
data = dtrain)
## The stopping iteration can be changes via simple indexing:
mod1 <- mod1[50000] ## Long runtime: 50000 iterations
## takes at least a couple of minutes on a standard machine
## Now take a look at the resulting combination
coef(mod1)
## Prediction on test data
preds <- predict(mod1, newdata = dtest)
## Evaluate the discriminatory power
UnoC(Surv(dtrain$time, dtrain$event), Surv(dtest$time, dtest$event), lpnew = -preds)
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